 The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon IFN alfa-2b in combination with ribavirin RBV may be effective in the treatment of chronic hepatitis D patients who are also infected by hepatitis B virus HBV. The purpose of this study is to test this hypothesis. The investigators will use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic hepatitis D virus HDV and HBV infection. A 24-week course of combination therapy pegylated IFNRBV will be used. 